J. Da silva

FHITlow/pHER2high signature in non‐small cell lung cancer is predictive of anti‐HER2 molecule efficacy

M. Polette, P. Birembaut, M. Dewolf, 2020, The Journal of pathology.

Radiotherapy-activated NBTXR3 nanoparticles modulate cancer cell immunogenicity and TCR repertoire

S. Paris, A. Darmon, J. Marill, 2022, Cancer Cell International.

NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model

S. Paris, M. Cortez, Jordan T. Pietz, 2022, Frontiers in Immunology.

Tumour cell blebbing and extracellular vesicle shedding: key role of matrikines and ribosomal protein SA

F. Maquart, J. Monboisse, H. Ouadid‐Ahidouch, 2019, British Journal of Cancer.

Structural characterization and in vivo pro-tumor properties of a highly conserved matrikine

J. Nuzillard, M. Molinari, A. Beljebbar, 2018, Oncotarget.

Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection

S. Paris, M. Cortez, N. Sahoo, 2023, JCI insight.